Cutera develops, manufactures, and sells energy-based medical aesthetic devices to dermatologists, plastic surgeons, and medical spas. Cutera's devices use lasers, intense pulsed light, and RF energy to perform cosmetic procedures including acne treatment, body contouring, hair removal, tattoo removal, skin revitalization, and vascular lesion treatment. Key platforms include AviClear (an FDA-cleared laser device for acne treatment), Secret by Cutera (RF microneedling), excel V/V+ (vascular and pigmented lesion treatment), truSculpt/truFlex (body contouring), Enlighten (tattoo removal), and xeo/xeo+ (a multi-application laser and light platform). Cutera sells directly to practitioners in North America, Australia, Japan, and major European markets, and through distributors in 37+ other countries. Revenue comes from three sources: upfront capital equipment sales, consumables (recurring per-procedure supplies for platforms like Secret RF and AviClear), and post-warranty service contracts. AviClear is Cutera's primary growth initiative — originally launched in 2022 under a lease model, Cutera relaunched it in late 2023 as a direct capital sales model with per-cycle consumable charges, which better aligns with how practitioners typically buy aesthetic devices. Consumables and services provide more predictable, higher-margin recurring revenue, while capital equipment sales are lumpier and more sensitive to macro and financing conditions.